1-3 of 3
David P. Tuck, MD
Close
Sort by
Journal Articles

Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma

Robert N Booher, PhD, Grzegorz S. Nowakowski, MD, Krish Patel, MD, Matthew A. Lunning, DO, Maria Elena S. Samson, B.S., Ruzanna Atoyan, MD, Anna W Ma, MS, Guang-Xin Xu, BS, Steven Dellarocca, B.S., Holly Modafferi, BS, Mylissa Borek, B.S., Zhidong Zhang, PhD, Jefferson Parker, PhD, Duncan Whitney, PhD, Hongwei Wang, MD, David P Tuck, MD, Anas Younes, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4168.
https://doi.org/10.1182/blood-2018-99-117383
Published: 2018
Journal Articles

A Pooled Analysis of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients Treated with the Dual PI3K and HDAC Inhibitor Fimepinostat (CUDC-907), Including Patients with MYC-Altered Disease

Daniel J. Landsburg, MD, Radhakrishnan Ramchandren, MD, Petronella J Lugtenburg, MD PhD, Kevin R. Kelly, MD PhD, Anas Younes, MD, Robert Gharavi, PharmD, David P. Tuck, MD, Stefan Klaus Barta, MD MRCP, MS
Journal: Blood
Blood (2018) 132 (Supplement 1): 4184.
https://doi.org/10.1182/blood-2018-99-112527
Published: 2018
Journal Articles

The Combination of Venetoclax and CUDC-907 Exhibits Synergistic Activity in Venetoclax-Refractory DLBCL

Kaiming Sun, PhD, Ruzanna Atoyan, MD, Mylissa A Borek, MS, Steven Dellarocca, MS, Garrett Rhyasen, PhD, Ali Fattaey, PhD, David P Tuck, MD
Journal: Blood
Blood (2016) 128 (22): 4184.
https://doi.org/10.1182/blood.V128.22.4184.4184
Published: 2016